Immunomedicsincwas A Clinical Stagebiopharmaceutical Company Founded In 1982Based In Morris Plainsnew Jerseythecompany Focused On Developing Monoclonal Antibody Based Therapies For Cancer Treatmentparticularly Antibody Drug Conjugatesadcsand Diagnostic Tools For Oncologyin 2020Immunomedics Was Acquired By Gilead Scienceswhich Integrated Its Portfolio Into Gileadaes Oncology Pipelinethecompany S Flagship Producttrodelvya Csacituzumab Govitecan Is An Adc Approved By Thefda For Metastatic Triplenegativebreast Cancer And Has Been Expanded For Other Indicationsimmunomedics Also Developed Diagnostic Technologies For Cancer Detection And Had Several Pipelinecandidates Targeting Various Solid Tumors And Hematologic Malignanciesfollowing Theacquisitiontrodelvy Becamea Cornerstonetherapy In Gilead S Offeringswith Significant Sales Projections Highlighting Its Commercial Potential
